XML 40 R27.htm IDEA: XBRL DOCUMENT v3.25.1
BALANCE SHEET COMPONENTS (Tables)
12 Months Ended
Dec. 31, 2024
BALANCE SHEET COMPONENTS  
Schedule of inventory

    

December 31,

2024

    

2023

    

As Restated*

Raw Materials

$

569,824

$

685,801

Work in Process

 

502,525

 

838,871

Finished Goods

 

1,964,870

 

1,851,145

Inventories

$

3,037,219

$

3,375,817

* See Note 12 – Restatement of Previously Issued financial information for details.

Schedule of property and equipment - net

Depreciation/

December 31

Amortization

    

2024

    

2023

    

Period

Furniture and fixtures

$

1,453,623

$

1,462,778

 

7 years

Equipment and computers

 

5,491,048

 

5,404,743

 

3 to 7 years

Leasehold improvements

 

6,282,710

 

6,224,863

 

Lesser of term of lease or estimated useful life

 

13,227,381

 

13,092,384

 

  

Less accumulated depreciation and amortization

 

4,224,998

 

3,036,030

 

  

Property and Equipment, Net

$

9,002,383

$

10,056,354

 

  

Schedule of other assets

December 31,

    

2024

    

2023

Patent applications pending

$

1,612,118

$

1,945,532

Patents issued

3,390,768

2,982,253

Less accumulated amortization of patents issued

 

(1,254,850)

 

(1,021,233)

Patents, net

 

3,748,036

 

3,906,552

Other

 

22,644

 

52,051

Other Assets

$

3,770,680

$

3,958,603

Schedule of patent amortization

2025

    

$

253,622

2026

 

252,481

2027

 

246,956

2028

 

234,087

2029

 

234,087

Thereafter

914,685

Scheduled amortization of patents issued

$

2,135,918

Schedule of accrued expenses and other current liabilities

December 31,

2024

    

2023

    

As Restated

Accrued salaries and commissions

$

3,387,675

$

3,344,080

Professional fees

769,577

956,432

Clinical studies

 

589,577

 

686,908

Deferred revenue

 

419,331

 

1,380,821

Other

 

865,510

 

991,545

Accrued expenses and other current liabilities

$

6,031,670

$

7,359,786

* See Note 12 – Restatement of Previously Issued financial information for details.